Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Raltegravir safe, effective in late pregnancy

Key clinical point: Better viral suppression should reduce risk of transmission to newborn.

Major finding: Among patients enrolled in weeks 29-37, viral suppression was higher in the raltegravir group (93%) compared with the efavirenz group (71%).

Study details: Randomized, controlled trial (n = 408).

Disclosures: The National Institutes of Health funded the study. Glaxo/ViiV, Merck, and Bristol-Myers Squibb supplied study drugs. Dr. Mirochnick has received research funding from those companies.

Citation:

Mark Mirochnick et al. CROI 2019, Abstract 39 LB.